Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Other Non-Current Liabilities (2020 - 2022)

Caribou Biosciences (CRBU) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $9000.0 as the latest value for Q1 2022.

  • Quarterly Other Non-Current Liabilities changed N/A to $9000.0 in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $9000.0 through Mar 2022, changed N/A year-over-year, with the annual reading at $17000.0 for FY2021, 90.34% down from the prior year.
  • Other Non-Current Liabilities for Q1 2022 was $9000.0 at Caribou Biosciences, down from $17000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $176000.0 in Q4 2020, with the low at $9000.0 in Q1 2022.
  • Average Other Non-Current Liabilities over 3 years is $103600.0, with a median of $153000.0 recorded in 2021.
  • Peak annual rise in Other Non-Current Liabilities hit 90.34% in 2021, while the deepest fall reached 90.34% in 2021.
  • Over 3 years, Other Non-Current Liabilities stood at $176000.0 in 2020, then plummeted by 90.34% to $17000.0 in 2021, then tumbled by 47.06% to $9000.0 in 2022.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $9000.0, $17000.0, and $153000.0 for Q1 2022, Q4 2021, and Q3 2021 respectively.